WilmerHale Advises Voyager Therapeutics in Strategic Collaboration With Neurocrine Biosciences

Download IconDownload Print IconPrint

WilmerHale Advises Voyager Therapeutics in Strategic Collaboration With Neurocrine Biosciences

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.
On January 29, 2019, Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. announced the formation of a strategic collaboration focused on the development and commercialization of Voyager's gene therapy programs for Parkinson’s disease and Friedreich's ataxia, as well as rights to two programs to be determined. This collaboration combines Neurocrine Biosciences’ expertise in neuroscience, drug development and commercialization with Voyager’s innovative gene therapy programs targeting severe neurological diseases. Under the terms of the agreement, Neurocrine Biosciences has agreed to pay Voyager $165 million in cash, including a $115 million upfront payment and a $50 million equity investment. Voyager will also receive funding from Neurocrine Biosciences for these collaboration programs and may be entitled to earn up to $1.7 billion in development, regulatory and commercial milestone payments across the four programs.

The WilmerHale team representing Voyager included Steven Singer, Jenna Ventorino and Elizabeth Mayo, with Brian Johnson, Avery Reaves and Ryan Crane advising on general corporate and equity investment matters.

Read more about the collaboration.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel